These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 19247656)

  • 1. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.
    Liu B; Wei J; Zou Z; Qian X; Nakamura T; Zhang W; Ding Y; Feng J; Yu L
    Eur J Hum Genet; 2007 Oct; 15(10):1049-53. PubMed ID: 17593927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
    Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
    Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.
    Ye F; Liu Z; Tan A; Liao M; Mo Z; Yang X
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):733-40. PubMed ID: 23299794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in metabolic GSTP1 and DNA-repair XRCC1 genes with an increased risk of DNA damage in pesticide-exposed fruit growers.
    Wong RH; Chang SY; Ho SW; Huang PL; Liu YJ; Chen YC; Yeh YH; Lee HS
    Mutat Res; 2008 Jul; 654(2):168-75. PubMed ID: 18603015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
    Liu YP; Ling Y; Zhang YP; Liu BR
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
    Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
    Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
    J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
    Rajkumar T; Samson M; Rama R; Sridevi V; Mahji U; Swaminathan R; Nancy NK
    Breast Cancer Res Treat; 2008 Nov; 112(1):81-7. PubMed ID: 18058229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients.
    Sreeja L; Syamala V; Hariharan S; Syamala VS; Raveendran PB; Sivanandan CD; Madhavan J; Ankathil R
    J Exp Ther Oncol; 2008; 7(1):73-85. PubMed ID: 18472644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
    Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
    Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the DNA repair gene XRCC1 and breast cancer.
    Duell EJ; Millikan RC; Pittman GS; Winkel S; Lunn RM; Tse CK; Eaton A; Mohrenweiser HW; Newman B; Bell DA
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):217-22. PubMed ID: 11303590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.